---
title: "Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286124993.md"
description: "William Blair analyst Andrew Brackmann has reiterated a Buy rating on Exagen (XGN) stock, citing strong Q1 performance and improving fundamentals. The company reported double-digit revenue growth, exceeding expectations, driven by higher test volumes and rising average selling prices. Management reaffirmed full-year guidance, with second-quarter trends surpassing last year. Brackmann highlights factors supporting further upside, including a maturing salesforce and growing contributions from new biomarkers. BTIG also issued a Buy rating with an $8.00 price target."
datetime: "2026-05-12T15:15:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286124993.md)
  - [en](https://longbridge.com/en/news/286124993.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286124993.md)
generator: "portal-rs"
---

# Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven

William Blair analyst Andrew Brackmann has reiterated their bullish stance on XGN stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Andrew Brackmann has given his Buy rating due to a combination of factors, including Exagen’s strong first-quarter performance and improving fundamentals. The company delivered double-digit revenue growth that exceeded expectations, driven by higher test volumes and rising average selling prices despite weather-related headwinds, while management reaffirmed full-year guidance and highlighted that second-quarter trends are already surpassing last year’s levels.

Brackmann also points to several tangible drivers that support further upside, such as a maturing salesforce, an expanding base of ordering clinicians, continued ASP gains, and growing contributions from new biomarkers and biopharma services backed by a sizable contract backlog. He believes these factors, together with ongoing pipeline development, gross margin expansion from lab efficiencies, and a visible path toward adjusted EBITDA breakeven, reduce model risk and justify a positive stance on the shares.

In another report released today, BTIG also reiterated a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [XGN.US](https://longbridge.com/en/quote/XGN.US.md)

## Related News & Research

- [A Peek at Exagen's Future Earnings](https://longbridge.com/en/news/278426924.md)
- [Quest Diagnostics teams with Humanity to offer biological age analysis on Questhealth.com](https://longbridge.com/en/news/296926398.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [09:57 ETHumanity führt über questhealth.com die Analyse des biologischen Alters in den USA ein](https://longbridge.com/en/news/296926366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**